Browse Myopic Choroidal Neovascularization

Myopic Choroidal Neovascularization (mCNV) is a serious eye condition that can lead to significant vision impairment if not properly managed. It is a complication associated with high myopia, a condition where the eyeball is longer than normal, causing light rays to focus in front of the retina rather than on it. This condition can lead to the development of new, abnormal blood vessels beneath the retina, which can leak fluid or blood, resulting in vision loss.

Causes of Myopic Choroidal Neovascularization

The primary cause of Myopic Choroidal Neovascularization is high myopia, also known as pathological myopia. This condition is characterized by excessive elongation of the eyeball, which can lead to degenerative changes in the retina and choroid. Over time, these changes can result in the formation of new blood vessels beneath the retina. Other contributing factors may include genetic predisposition, environmental influences, and lifestyle factors such as prolonged near work and lack of outdoor activities.

Symptoms of Myopic Choroidal Neovascularization

Symptoms of mCNV can vary, but they typically include:

• Blurred vision: This is often the first noticeable symptom, as the abnormal blood vessels can distort the retina.
• Distorted vision: Straight lines may appear wavy or bent.
• Dark spots: Patients may notice dark or empty areas in their vision.
• Reduced color vision: Colors may appear less vibrant or washed out.
• Sudden vision loss: In severe cases, there may be a rapid decrease in vision.

Treatment of Myopic Choroidal Neovascularization

The treatment of mCNV focuses on stopping the growth of abnormal blood vessels and preserving vision. Several treatment options are available:

Anti-VEGF Therapy

Anti-VEGF (vascular endothelial growth factor) medications are the most common treatment for mCNV. These drugs work by inhibiting the growth of new blood vessels. Some of the medications available include:

• Lucentis: A widely used anti-VEGF medication that is injected directly into the eye.
• Avastin: Another anti-VEGF drug that is often used off-label for mCNV.
• Eylea: An effective treatment option that is also administered via injection.

Photodynamic Therapy (PDT)

PDT involves the use of a light-sensitive drug that is activated by a laser to destroy abnormal blood vessels. This treatment is less commonly used today due to the effectiveness of anti-VEGF therapy.

Laser Photocoagulation

This treatment uses a laser to seal off leaking blood vessels. However, it is not commonly used for mCNV due to the risk of damaging the surrounding retina.

Prevention of Myopic Choroidal Neovascularization

While it may not be possible to completely prevent mCNV, certain measures can help reduce the risk:

• Regular eye examinations: Early detection of high myopia and monitoring for signs of mCNV can help manage the condition effectively.
• Protective eyewear: Wearing sunglasses with UV protection can help protect the eyes from harmful rays.
• Healthy lifestyle: Maintaining a balanced diet rich in antioxidants and omega-3 fatty acids can support eye health.
• Limiting screen time: Reducing prolonged exposure to screens and taking regular breaks can help reduce eye strain.

In conclusion, Myopic Choroidal Neovascularization is a serious condition that requires prompt attention and treatment to prevent vision loss. With advancements in medical treatments, such as anti-VEGF therapy, there are effective options available to manage this condition. If you or someone you know is experiencing symptoms of mCNV, it is crucial to seek professional medical advice and explore treatment options, including medications like Lucentis, Avastin, and Eylea, which are available for purchase.